Forskning
Udskriv Udskriv
Switch language
  1. Rigshospitalet
  2. Publikationer
  3. Dopaminerge lægemidler til beh...
  4. Citationsformater
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Dopaminerge lægemidler til behandling af depression

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Harvard

Burmester, D, von Buchwald, CM & Videbech, P 2021, 'Dopaminerge lægemidler til behandling af depression', Ugeskrift for Laeger, bind 183, nr. 47. <https://ugeskriftet.dk/videnskab/dopaminerge-laegemidler-til-behandling-af-depression>

APA

Burmester, D., von Buchwald, C. M., & Videbech, P. (2021). Dopaminerge lægemidler til behandling af depression. Ugeskrift for Laeger, 183(47). https://ugeskriftet.dk/videnskab/dopaminerge-laegemidler-til-behandling-af-depression

CBE

Burmester D, von Buchwald CM, Videbech P. 2021. Dopaminerge lægemidler til behandling af depression. Ugeskrift for Laeger. 183(47).

MLA

Burmester, Daniel, Carl Michael von Buchwald og Poul Videbech. "Dopaminerge lægemidler til behandling af depression". Ugeskrift for Laeger. 2021. 183(47).

Vancouver

Burmester D, von Buchwald CM, Videbech P. Dopaminerge lægemidler til behandling af depression. Ugeskrift for Laeger. 2021 nov. 22;183(47).

Author

Burmester, Daniel ; von Buchwald, Carl Michael ; Videbech, Poul. / Dopaminerge lægemidler til behandling af depression. I: Ugeskrift for Laeger. 2021 ; Bind 183, Nr. 47.

Bibtex

@article{3da8a72505d84cac83f6a8cda51476eb,
title = "Dopaminerge l{\ae}gemidler til behandling af depression",
abstract = "A significant proportion of patients with depression do not respond to classic antidepressants addressing serotonergic or noradrenergic neurotransmission. Certain clinical features of depression seem to involve dopaminergic neurotransmission. Although medications with specific dopaminergic actions are used in the treatment of depression in other countries (e.g. the United States), these drugs are rarely mentioned in Danish treatment guidelines. This review aims at comprehending current dopaminergic treatment strategies and future directions in this field.",
keywords = "Antidepressive Agents/therapeutic use, Depression/drug therapy, Dopamine, Dopamine Agents, Humans, Norepinephrine",
author = "Daniel Burmester and {von Buchwald}, {Carl Michael} and Poul Videbech",
year = "2021",
month = nov,
day = "22",
language = "Dansk",
volume = "183",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "47",

}

RIS

TY - JOUR

T1 - Dopaminerge lægemidler til behandling af depression

AU - Burmester, Daniel

AU - von Buchwald, Carl Michael

AU - Videbech, Poul

PY - 2021/11/22

Y1 - 2021/11/22

N2 - A significant proportion of patients with depression do not respond to classic antidepressants addressing serotonergic or noradrenergic neurotransmission. Certain clinical features of depression seem to involve dopaminergic neurotransmission. Although medications with specific dopaminergic actions are used in the treatment of depression in other countries (e.g. the United States), these drugs are rarely mentioned in Danish treatment guidelines. This review aims at comprehending current dopaminergic treatment strategies and future directions in this field.

AB - A significant proportion of patients with depression do not respond to classic antidepressants addressing serotonergic or noradrenergic neurotransmission. Certain clinical features of depression seem to involve dopaminergic neurotransmission. Although medications with specific dopaminergic actions are used in the treatment of depression in other countries (e.g. the United States), these drugs are rarely mentioned in Danish treatment guidelines. This review aims at comprehending current dopaminergic treatment strategies and future directions in this field.

KW - Antidepressive Agents/therapeutic use

KW - Depression/drug therapy

KW - Dopamine

KW - Dopamine Agents

KW - Humans

KW - Norepinephrine

M3 - Review

C2 - 34851261

VL - 183

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 47

ER -

ID: 69562994